Early local therapy in combination with PD-1/PD-L1 inhibitors in oligometastatic non-small cell lung cancer: results from a prospective multicenter observational study.

ABSTRACT:

Purpose

Appropriate local therapy may provide survival benefits in oligometastatic non-small cell lung cancer (NSCLC) patients receiving chemotherapy or targeted therapy. However, its roles in immunotherapy-treated patients have not been fully understood.

Methods

PD-1/PD-L1 inhibitor-treated metastatic NSCLC patients were enrolled in a prospective multi-center observational study (NCT04766515) from September 2020 to March 2023. Those without driver mutations, with measurable disease and harboring oligometastatic disease were included. Progression-free survival (PFS) and overall survival (OS) were compared between those with or without early local therapy (eLT). Moreover, eLT performed within or after 1 month of the initiation of PD-1/PD-L1 inhibitors was defined as concurren

SUBMITTER: Gao J 

PROVIDER: S-EPMC11923308 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature